

Dear Editors,

Thank you for the constructive comments provided by the reviewers regarding the manuscript "Chronic Hepatitis C Genotype 6". I and my co-authors have gone over all of them carefully and have addressed them to the best of our ability and have provided a point by point response as well as a revised manuscript with changes highlighted with red color. The title of the article has been shortened. We have modified the manuscript and references according to the journal format, and as per the editorial team's comments. The powerpoint file of Figure 1 is provided.

Point-by-point responses

Reviewer 1. The paper reviews the Chronic Hepatitis C Genotype 6. The review is interesting few points could be better addressed. 1-A short chapter about extrahepatic manifestations of Hepatitis C Genotype 6 could be introduced. See for example: HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis. 2007 Sep;39 Suppl 1:S13-21. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009 Jan;5(1):26-34 2- Among cytokines CXCL10 and others could be better evaluated in Hepatitis C Genotype 6. See for example. Cytokines and HCV-related disorders. Clin Dev Immunol. 2012;2012:468107. 3- English language needs to be corrected.

We have added a short paragraph on extrahepatic manifestations of HCV genotype 6. There is no specific data on HCV-related cytokines for HCV genotype 6.

Reviewer 2. This is a very focused review and well written. 1. In the abstract, abbreviations SVR (line 9) and EVR (line 19) should be spelled out when they are used at the first time. 2. Table 1: suggest to move "Prevalence of HCV genotype 6" to the first column". Author/Year" the last. "Population" should "the number of patients" or "case number". 3. Tables 2 and 3: suggest to move "Study" to the last column. This column basically is the reference.

We have spelled out SVR and EVR in the abstract part. Table 1 has been modified per the reviewer's comment. For Tables 2 and 3, we believe that it is better to keep the country of origin of the studies in the first column because of its relevance to the interpretation.

3. This review article exhibited the hepatitis C virus (HCV) genotype 6 characteristics including response guided interferon treatment for this south-east Asia local genotype. There is enough information about this virus. Following additional information might be added if possible. Major 1. In the "Classification and Diagnosis", the characteristics of genotype 6 concerning the sequences specific for interferon sensitivity determining region (ISDR) or interferon and ribavirin resistance determining region (IRRDR) in genotype 1b might be added. If there is no data concerning such viral full sequence and the clinical characters, this "no data" information must be added for understanding the present knowledge of this genotype. Minor typing errors 1. "Introduction" line 3: 'worldwidein' should be 'worldwide in' 2. "Epidemiology of HCV genotype 6" the last sentence 'intravenous drug injection intravenous drug injection' should be 'intravenous drug injection'

We have corrected all typing-errors as suggested. We have added a paragraph on ISDR mutations in the treatment part as it is related to treatment outcomes.